SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-24-002718
Filing Date
2024-01-10
Accepted
2024-01-10 16:25:25
Documents
12
Period of Report
2024-01-10
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea191340-8k_nektar.htm   iXBRL 8-K 26493
  Complete submission text file 0001213900-24-002718.txt   198192

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE nktr-20240108.xsd EX-101.SCH 3009
3 XBRL LABEL FILE nktr-20240108_lab.xml EX-101.LAB 34240
4 XBRL PRESENTATION FILE nktr-20240108_pre.xml EX-101.PRE 22355
6 EXTRACTED XBRL INSTANCE DOCUMENT ea191340-8k_nektar_htm.xml XML 3215
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

IRS No.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 24526868
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)